Ensuring Resilience: How Life Science is Reshaping Supply Chains in Response to COVID-19

Industry trends
Supply chain

COVID-19 put life sciences supply chains under unprecedented pressure. Almost overnight, the long, global supply chains created in an era of easy cross-border trade were hit by national lockdowns that made it harder to keep getting products to patients. The experience forced companies to consider the effect of globalization on supply chain resilience, driving growing interest in reshoring operations.

COVID-19 confirmed theoretical concerns about supply chain resilience at a time of global workforce disruption and surging demand for particular pharmaceutical products.

To understand how that experience is shaping attitudes toward resilience, Informa Pharma Intelligence and Cambrex surveyed 117 leaders, mainly from biopharma companies. Around half of the respondents outsourced at least part of their supply chain to a contract development and manufacturing organization (CDMO).

Read our whitepaper to learn how the industry’s view on supply chain resiliency have changed, and the steps companies are taking to better navigate future obstacles.